In This Issue:
- Confusion Persists in Anticipation of 340B “Mega-Rule”
- Implementation of the Affordable Care Act
- Other Federal Regulatory Initiatives
- Other Congressional and State Initiatives
- Other Health Care News
- Upcoming Hearings and Markups
- Excerpt from Confusion Persists in Anticipation of 340B “Mega-Rule”:
The 340B drug discount program continues to be one of the most scrutinized and anticipated areas of health policy regulation going into the summer. The 340B program provides discounts between 20 and 50 percent off the cost of pharmaceuticals to providers, such as hospitals and community health centers. While the program was initially created to provide affordable access to providers serving overwhelmingly needy communities, the ACA’s expansion of eligible providers to critical access hospitals (CAHs) and children’s hospitals, among others, has drawn the intense scrutiny of lawmakers and drug manufacturers alike.
Please see full publication below for more information.
